Amryt Pharma PLC Company Profile (LON:FAST)

About Amryt Pharma PLC (LON:FAST)

Amryt Pharma PLC logoAmryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company's lead products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. The Company holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol (bad cholesterol) from the blood.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: LON:FAST
  • CUSIP: N/A
  • Web: www.amrytpharma.com/
Average Prices:
  • 52 Week Range: GBX 1.85 - GBX 3.90
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0
Profitability:
  • Net Margins: -223.72%
  • Return on Equity: -104.94%
  • Return on Assets: -40.64%
Misc:
  • Average Volume: 939,809 shs.
 

Frequently Asked Questions for Amryt Pharma PLC (LON:FAST)

What is Amryt Pharma PLC's stock symbol?

Amryt Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "FAST."

Where is Amryt Pharma PLC's stock going? Where will Amryt Pharma PLC's stock price be in 2017?

2 brokerages have issued 12 month target prices for Amryt Pharma PLC's stock. Their forecasts range from GBX 60 to GBX 65. On average, they expect Amryt Pharma PLC's stock price to reach GBX 62.50 in the next year. View Analyst Ratings for Amryt Pharma PLC.

Who are some of Amryt Pharma PLC's key competitors?

Who are Amryt Pharma PLC's key executives?

Amryt Pharma PLC's management team includes the folowing people:

  • Joe Wiley, Chief Executive Officer, Executive Director
  • Rory Nealon, Chief Financial Officer, Chief Operating Officer, Executive Director, Company Secretary
  • Harry Thomas Stratford, Independent Non-Executive Chairman of the Board
  • James Culverwell, Senior Non-Executive Independent Director
  • Ray Stafford, Non-Executive Independent Director
  • Markus Ziener, Non-Executive Independent Director

How do I buy Amryt Pharma PLC stock?

Shares of Amryt Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Amryt Pharma PLC's stock price today?

One share of Amryt Pharma PLC stock can currently be purchased for approximately GBX 2.97.


MarketBeat Community Rating for Amryt Pharma PLC (LON FAST)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Amryt Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amryt Pharma PLC (LON:FAST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: GBX 62.50
Consensus Price Target History for Amryt Pharma PLC (LON:FAST)
Price Target History for Amryt Pharma PLC (LON:FAST)
Analysts' Ratings History for Amryt Pharma PLC (LON:FAST)
Show:
DateFirmActionRatingPrice TargetDetails
9/24/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 65View Rating Details
4/24/2017Stifel NicolausReiterated RatingBuyGBX 60View Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Amryt Pharma PLC (LON:FAST)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Amryt Pharma PLC (LON:FAST)
Current Year EPS Consensus Estimate: $-0.33 EPS

Dividends

Dividend History for Amryt Pharma PLC (LON:FAST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amryt Pharma PLC (LON:FAST)
Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2015Friel,CathalInsiderBuy3,555,394GBX 4£142,215.76
6/26/2015Friel,CathalInsiderBuy17,308,080GBX 0.04£6,923.23
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Amryt Pharma PLC (LON:FAST)
Latest Headlines for Amryt Pharma PLC (LON:FAST)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.

Chart

Amryt Pharma PLC (FAST) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.